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Background
Enhanced eosinophil extravasation into the tissue is a
characteristic feature of bronchial asthma and other aller-
gic diseases. The barrier-forming vascular endothelial cells
release prostaglandin I2 (PGI2, prostacyclin) as the major
prostanoid, and it has been previously observed that PGI2
receptor (IP)-deficient mice show enhanced eosinophilic
inflammation in response to allergens. Our aim was to
define the role of PGI2 in endothelial function and in eosi-
nophil trafficking across endothelial monolayers.
Methods
Eosinophils were freshly isolated from human blood.
Eosinophil chemotaxis through cell-free filters and adhe-
sion to fibronectin were studied. Cell interaction assays,
like adhesion and transmigration of eosinophils, were
performed on confluent monolayers of human lung
microvascular endothelial cells. The endothelial barrier
properties were analyzed by measurements of transend-
othelial electrical resistance (TEER). Morphological stud-
ies were performed with immunofluorescence
microscopy.
Results
Exogenous PGI2 markedly attenuated the chemotaxis of
isolated eosinophils through cell-free filters. This effect
was prevented by the IP receptor antagonist CAY10441
and the adenylyl cyclase inhibitor SQ29548. Expression
of IP receptors on eosinophils was shown by indirect flow
cytometry and Western blot. PGI2 reduced eosinophil
adhesion to fibronectin, inhibited the activation and up-
regulation of CD11b/CD18 adhesion molecule, and
blocked podosome formation in response to eotaxin.
PGI2 production of endothelial cells was abolished by
diclofenac, a non-selective COX inhibitor, which resulted
in enhanced eosinophil adhesion to endothelial monol-
ayers. Similarly, the IP receptor antagonist CAY10441
enhanced the adhesion of eosinophils to endothelial
cells. Transendothelial migration of eosinophils was like-
wise augmented by diclofenac. The diclofenac treatment
itself decreased the electrical resistance of endothelial
monolayers and disrupted the intercellular junctions as
visualized by VE-cadherin and F-actin staining.
Conclusion
Based on these observations, endothelium-derived PGI2
might be an important protective factor in keeping inap-
propriate eosinophil infiltration under control and might
modulate allergic responses by inhibiting eosinophil
responsiveness to chemoattractants in terms of adhesion
and migration, and by strengthening the barrier function
of the endothelium against infiltrating leukocytes. There-
fore, IP agonists might be a useful therapeutic option for
otherwise inadequately controlled inflammation in eosi-
nophilic diseases, by blunting their extravasation into tis-
sue.
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